期刊文献+

三联叠加疗法对慢性乙型肝炎患者乙型肝炎病毒复制和变异的影响 被引量:2

Influence of a triplex superimposed treatment on HBV replication and mutation during treating chronic hepatitis B
原文传递
导出
摘要 目的 观察疗效确切的抗病毒药物和免疫调节剂 ,叠加伍用对慢性乙型肝炎病人HBV复制和变异的影响。方法 应用拉米夫定、干扰素α 2b、黄芪注射液三联叠加疗法 ,对慢性乙型肝炎病人进行抗病毒治疗 ,并与单独应用拉米夫定的抗HBV效果进行比较评价。检测HBVDNA阴转率和HBeAg 抗HBe血清转换率 ;血清HBVDNA浓度 ;HBVDNA的YMDD变异率和前C区变异率。结果 A组 (叠加用药组 )与B组 (拉米夫定单药组 )比较 ,HBVDNA阴转率分别在第 12周、36周及 48周差异有显著性 (P <0 0 5 ) ,HBeAg阴转率在第 36周、48周差异有显著性 (P <0 0 5 ) ,抗HBe阳转率仅在第 48周差异有显著性 (P <0 0 5 ) ;两组患者血清HBVDNA浓度比较 ,治疗 12周时降低程度差异有显著性 (P <0 0 5 ) ,治疗第 36周和 48周时差异有非常显著性 (P <0 0 1) ;治疗后 12周 ,A组出现前C区BCP变异 ;疗后 2 4周、36周和 48周 ,两组均出现YMDD和前C区变异。结论 与拉米夫定单独用药比较 ,三联叠加疗法可增加慢性乙型肝炎患者HBVDNA阴转率和HBeAg 抗HBe血清转换率 ,更显著降低血清HBVDNA浓度 ,并减少YMDD变异 ,故其抗HBV疗效优于拉米夫定单独用药。 Objective To observe and evaluate the influence of a new antiviral treatment scheme on HBV replication and mutation during treating chronic hepatitis B.Methods Ⅰ. In the test group, lamivudine, IFN α 2b, Astragalus membranaceus were chosen as a triplex superimposed treatment scheme for treating the patients who were on the state of HBV high replication and involved in the clinical condition of chronic hepatitis B. The control group was treated with lamivudine alone. Ⅱ. The observed parameters percentage of patients in whom HBV DNA became undetectable (serum HBV DNA<1.6 ng/L), HBeAg/anti HBe seroconversion rate; HBV DNA serum level; HBV YMDD mutation rate and pre C region mutation rate.Results Compared with that of the control group, HBV DNA undetectable rate of the test group increased markedly at weeks 12,36,48( P<0.05) , HBeAg negative rate of the group increased markedly at week 36,48( P<0.05) , while anti HBe positive rate increased only at week 48 (31.58 vs.19.23%, P<0.05). After 4 weeks of treatment, HBV DNA serum level of both the test group and the control group reduced very remarkably ( P<0.01) , and at week 48, reduced more significantly ( P<0.001) . Compared with the control group, HBV DNA serum level of the test group reduced notably at week 12 ( P<0.05) and very notable at week 36 and 48( P<0.01) . At week 12, the pre C region mutation occurred in the test group, and at week 24,36,48,the pre C region and YMDD mutations occurred in both the test group and the control group.Conclusion As to anti viral treatment of chronic hepatitis B, the triplex superimopsed treatment had better efficacy than lamivudine alone.
出处 《中华实验和临床病毒学杂志》 CAS CSCD 北大核心 2001年第3期236-236,共1页 Chinese Journal of Experimental and Clinical Virology
关键词 干扰素 黄芪 乙型肝炎病毒 基因变异 拉米夫定 Interferon Astragalus membranaceus Hepatitis B virus Replication and mutation \ Lamivudine
  • 引文网络
  • 相关文献

参考文献7

二级参考文献4

  • 1Yao G B,Chin Med J,1999年,112卷,387页
  • 2Lai C L,N Eng J Med,1998年,339卷,61页
  • 3Lai C L,Hepatology,1997年,25卷,241页
  • 4Doong S L,Proc Natl Acad Sci,1991年,88卷,8495页

共引文献462

同被引文献13

引证文献2

二级引证文献32

相关主题

;
使用帮助 返回顶部